@article{ACR5196,
author = {Zulfiya Syunyaeva and Katharina Berghof and Diego Kauffmann-Guerrero and Jeremias Götschke and Amanda Tufman and Kathrin Kahnert},
title = {Late-onset severe pneumonitis under osimertinib},
journal = {AME Case Reports},
volume = {3},
number = {0},
year = {2019},
keywords = {},
abstract = {Pneumonitis is a rare and possibly life threatening side effect of TKI-treatment. We present a patient with adenocarcinoma of the lung harboring an uncommon EGFR Exon 21 mutation treated with osimertinib as second-line therapy. After nine months of treatment, the patient developed progressing shortness of breath and night sweats. A severe late-onset predominantly eosinophilic pneumonitis was diagnosed, osimertinib treatment was discontinued and immunosuppressive treatment was initiated. This case report highlights late-onset pneumonitis as a side effect of third-generation TKI-treatment and possible options for subsequent tumor treatment.},
issn = {2523-1995}, url = {https://acr.amegroups.org/article/view/5196}
}